Roche reports very strong sales growth in the first nine months of 2019 – outlook raised

Group sales increase 10% at constant exchange rates and 9% in Swiss francs, due to new products Pharmaceuticals Division sales up 12%, driven by high demand for recently launched medicines, mainly Ocrevus, Hemlibra, Tecentriq and Perjeta Diagnostics Division sales grow 4%, primarily due to its immunodiagnostic testing portfolio
Source: Roche Media News - Category: Pharmaceuticals Source Type: news